Skip to main content
Institutional deep-dive - valuation, health, statements

Financial Analysis

Filing-based analysis. Market pricing is not included. Fundamentals from SEC filings; economic data from FRED and the BLS. About our data

Fundamentals

NRX Pharmaceuticals, Inc. NRXP

· Materials · Pharmaceutical Preparations

FY2025 10-K, filed 2026-03-23
SEC EDGAR

Filing evidence summary

Caution evidenceCoverage 3/5 core metrics

Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

Backward-looking filed evidence under visible rules - not a rating, forecast or investment advice. Missing data is never scored.

Evidence signals

  • Shareholders' equity was non-positive

    Debt/equity is shown as not meaningful rather than as a negative leverage ratio.

    Why this surfaced

    Same-period reported shareholders' equity was zero or negative; review the balance sheet and capital structure. Period end 2025-12-31.

  • 5 filing risk checks flagged

    Flagged areas: Solvency & liquidity, Dilution.

    Why this surfaced

    The full financial analysis shows each value, threshold, and sector limitation.

Core trend metrics

Latest annual operating margin
-1324.4%
as of 2025-12-31
Debt / equity
N/M
as of 2025-12-31
ROIC snapshot
-129.5%
period varies

Hover a tile for its exact definition; the Statements tab carries per-cell filing citations.

Where to look next

Risk checks

5of 8 rule-based checks flagged
  • Solvency & liquidity
  • Dilution

Financial movement

  • Cash→ flat
  • Long-term debt→ flat
  • Inventory→ flat
  • Receivables→ flat
  • Current assets→ flat

Source & freshness

Source
SEC EDGAR XBRL
Fetched
2026-10-21
Latest period end
2025-12-31
Filings
EDGAR ↗

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-03-23prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • Therapy$854K
    69.7%
    no prior
  • Procedures$371K
    30.3%
    no prior

Members sum to the consolidated $1.23M for this period.

Latest quarter
Quarter ending 2026-06-3010-Q filed 2026-08-14prior period 2026-03-31 from the same filingView filing
  • Therapy$871K
    79.1%
    no prior
  • Procedures$230K
    20.9%
    no prior

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

Peer percentiles

latest fiscal year ending 2025-12-31 · among 4,060 US-listed filers · 790 in Materials
MetricValuevs all filersvs sector
Revenue
latest fiscal-year revenue as filed
$1M
4thof 3,247
bottom third
11thof 512
bottom third
Operating margin
operating income ÷ revenue
-1324.4%
6thof 2,777
bottom third
18thof 474
bottom third
Net margin
net income ÷ revenue
-2336.5%
4thof 3,212
bottom third
14thof 508
bottom third
Stock comp ÷ revenue
stock-based compensation ÷ revenue · lower is ranked higher
18.6%
17thof 2,852
bottom third
37thof 466
middle third
Days sales outstanding
receivables ÷ revenue × 365 · lower is ranked higher
48 days
52ndof 2,373
middle third
57thof 382
middle third
Cash-flow accrual ratio
(net income − operating cash flow) ÷ average total assets · lower is ranked higher
-174.8%
99thof 3,845
top third
98thof 752
top third
Balance-sheet accrual ratio
change in net operating assets ÷ average net operating assets · lower is ranked higher
-3.9%
66thof 3,301
middle third
58thof 662
middle third

Each filer's latest fiscal year as stored by the nightly crawl; fiscal year ends differ across the universe. A metric ranks only filers for which it is computable from filed facts. Ties split; a rank reads "better than N% of filers" in the metric's own direction. Descriptive and educational, not a rating.

Earnings quality

latest fiscal year ending 2025-12-31 · accruals and cash conversion as filed
Cash conversion
-
operating cash flow ÷ net income, latest fiscal year
Cash-flow accrual ratio
-174.7%
(net income − operating cash flow) ÷ average total assets
Balance-sheet accrual ratio
-3.9%
change in net operating assets ÷ average net operating assets
Cash-backed years
4 of 5
fiscal years where operating cash flow met or exceeded net income
Mean cash conversion
-
across the stored fiscal years with positive net income

Per fiscal year from filed facts: cash conversion = operating cash flow / net income (net income > 0); cash-flow accrual ratio = (net income - operating cash flow) / average total assets; balance-sheet accrual ratio = change in net operating assets / average net operating assets, NOA = (assets - cash) - (liabilities - debt). Descriptive; a missing input yields a missing ratio. High accrual ratios and cash conversion well below one are the measures the accruals literature associates with less persistent earnings; they are screens to read the cash-flow statement with, not conclusions. The per-year series is part of Pro risk analysis.

Point-in-time ledger

first-reported vs latest filing · periods since 2020-01-01 · 35 changed periods, 26 largest shown
Line itemPeriodFirst reportedLatest filingChangeFilings
Net income
NetIncomeLoss
fiscal year 2020-12-31-$434K
10-K 2021-04-01
-$51.8M
10-K 2022-03-31
-11818.9%first · latest · 3 filings carry it
Operating income
OperatingIncomeLoss
quarter 2021-03-31-$236K
10-Q 2021-05-21
-$25.6M
10-Q 2022-05-16
-10768.9%first · latest
Operating income
OperatingIncomeLoss
fiscal year 2020-12-31-$907K
10-K 2021-04-01
-$51.4M
10-K 2022-03-31
-5563.1%first · latest · 3 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2021-06-30$515K
10-Q 2021-08-16
$22.8M
10-Q/A 2022-08-12
+4335.7%first · latest
Net income
NetIncomeLoss
quarter 2020-09-30-$126K
10-Q 2020-11-16
-$5.16M
10-Q/A 2022-08-12
-4003.8%first · latest · 3 filings carry it
Operating income
OperatingIncomeLoss
quarter 2020-09-30-$169K
10-Q 2020-11-16
-$5.15M
10-Q/A 2022-08-12
-2946.4%first · latest · 3 filings carry it
Net income
NetIncomeLoss
quarter 2021-03-31-$894K
10-Q 2021-05-21
-$25.5M
10-Q 2022-11-14
-2752.0%first · latest · 8 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2020-12-31$2.77M
10-K 2021-04-01
-$43.8M
10-K 2023-03-31
-1680.8%first · latest · 12 filings carry it
Operating cash flow
NetCashProvidedByUsedInOperatingActivities
quarter 2021-03-31-$179K
10-Q 2021-05-21
-$3.02M
10-Q 2022-05-16
-1585.3%first · latest
Total liabilities
Liabilities
balance at 2020-12-31$3.28M
10-K 2021-04-01
$46.7M
10-Q/A 2022-08-12
+1323.5%first · latest · 8 filings carry it
Net income
NetIncomeLoss
quarter 2020-03-31$273K
10-Q 2020-05-15
-$1.59M
10-Q/A 2022-08-12
-682.0%first · latest · 8 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2021-03-31$1.22M
10-Q 2021-05-21
$6.39M
10-Q 2022-11-14
+423.8%first · latest · 8 filings carry it
Operating cash flow
NetCashProvidedByUsedInOperatingActivities
fiscal year 2020-12-31-$599K
10-K 2021-04-01
-$2.27M
10-K 2022-03-31
-278.4%first · latest · 3 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2020-06-30$3.63M
10-Q 2020-08-14
-$5.92M
10-Q/A 2022-08-12
-263.3%first · latest · 6 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2020-03-31$3.78M
10-Q 2020-05-15
-$6.12M
10-Q/A 2022-08-12
-262.0%first · latest · 8 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2020-09-30$3.2M
10-Q 2020-11-16
-$2.83M
10-Q/A 2022-08-12
-188.4%first · latest · 3 filings carry it
Net income
NetIncomeLoss
quarter 2020-06-30-$150K
10-Q 2020-08-14
$102K
10-Q/A 2022-08-12
+168.4%first · latest · 6 filings carry it
Operating income
OperatingIncomeLoss
quarter 2020-06-30-$181K
10-Q 2020-08-14
$105K
10-Q/A 2022-08-12
+157.8%first · latest · 3 filings carry it
Stockholders' equity
StockholdersEquity
balance at 2021-06-30-$17.4M
10-Q 2021-08-16
-$39.8M
10-Q 2022-11-14
-128.1%first · latest · 6 filings carry it
Debt issued
ProceedsFromNotesPayable
fiscal year 2020-12-31$274K
10-K 2021-04-01
$620K
10-K 2022-03-31
+126.1%first · latest · 3 filings carry it
Net income
NetIncomeLoss
quarter 2021-06-30-$16M
10-Q 2021-08-16
-$117K
10-Q 2022-11-14
+99.3%first · latest · 6 filings carry it
Net income
NetIncomeLoss
quarter 2021-09-30-$20.8M
10-Q 2021-11-15
-$37M
10-Q 2022-11-14
-78.3%first · latest · 3 filings carry it
Basic shares
WeightedAverageNumberOfSharesOutstandingBasic
quarter 2023-03-3167,453,897 shares
10-Q 2023-05-15
16,410,062 shares
10-Q 2025-05-15
-75.7%first · latest · 3 filings carry it
Deferred revenue (current)
ContractWithCustomerLiabilityCurrent
balance at 2021-09-30$775K
10-Q 2021-11-15
$1.26M
10-Q/A 2022-08-12
+62.7%first · latest
Total liabilities
Liabilities
balance at 2021-06-30$36M
10-Q 2021-08-16
$58.3M
10-Q/A 2022-08-12
+62.1%first · latest
Operating income
OperatingIncomeLoss
quarter 2023-03-31-$9.44M
10-Q 2023-05-15
-$3.85M
10-Q 2025-05-15
+59.2%first · latest · 3 filings carry it

4 share-count periods re-presented for a stock split (1-for-10) are listed apart from restatements and not counted above.

First filing reporting each period vs the latest filing carrying it (10-K and 10-Q only, periods since 2020, the extractor's winning tag per concept); a change under 0.5% is treated as rounding. A change can be a restatement, a reclassification or a re-tagging in a later comparative column; the two filings are linked so the reader can see which. Descriptive, not a verdict.

Notes by disclosure type

Not available for NRXP yet: no footnote text blocks on file for this filer in the ingested DERA files.

Fundamentals from SEC EDGAR. Scores, the DCF, and every model shown are educational analysis, not investment advice or price predictions.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.